| Literature DB >> 35743039 |
Anita Raducka1, Marcin Świątkowski1, Izabela Korona-Głowniak2, Barbara Kaproń3, Tomasz Plech4, Małgorzata Szczesio1, Katarzyna Gobis5, Małgorzata Iwona Szynkowska-Jóźwik1, Agnieszka Czylkowska1.
Abstract
Developing new, smart drugs with the anticancer activity is crucial, especially for cancers, which cause the highest mortality in humans. In this paper we describe a series of coordination compounds with the element of health, zinc, and bioactive ligands, benzimidazole derivatives. By way of synthesis we have obtained four compounds named C1, C2, C4 and C4. Analytical analyses (elemental analysis (EA), flame atomic absorption spectrometry (FAAS)), spectroscopic (Fourier transform infrared spectroscopy (FT-IR), mass spectrometry (MS)) and thermogravimetric (TG) methods and the definition of crystal structures were used to explore the nature of bonding and to elucidate the chemical structures. The collected analytical data allowed the determination of the stoichiometry in coordination compounds, thermal stability, crystal structure and way of bonding. The cytotoxicity effect of the new compounds as a potential antitumor agent on the glioblastoma (T98G), neuroblastoma (SK-N-AS) and lung adenocarcinoma (A549) cell lines and human normal skin fibroblasts (CCD-1059Sk) was also determined. Cell viability was determined by the MTT assay. The results obtained confirmed that conversion of ligands into the respective metal complexes significantly improved their anticancer properties. The complexes were screened for antibacterial and antifungal activities. The ADME technique was used to determine the physicochemical and biological properties.Entities:
Keywords: ADME analysis; FTIR spectra; MTT assay; adenocarcinoma; benzimidazole derivatives; biological activity; biomedical applications; bioorganometallic chemistry; coordination compounds; glioblastoma; lung cancer; medicinal inorganic chemistry; metal complexes; metallodrugs; neuroblastoma; pharmacological activity; structural studies; thermogravimetric analysis
Mesh:
Substances:
Year: 2022 PMID: 35743039 PMCID: PMC9224258 DOI: 10.3390/ijms23126595
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Scheme 1Synthesis of ligand 1 (L1) and 2 (L2).
Scheme 2Synthesis of ligands 3 (L3) and 4 (L4).
Scheme 3Synthesis of solid zinc (II) coordination compounds.
Percentage composition of the elements in coordination compounds.
| C1 | C2 | C3 | C4 |
|---|---|---|---|
| M = 701.5093 g/mol | M = 664.4940 g/mol | M = 662.9722 g/mol | M = 822.7802 g/mol |
| yield (43%) | yield (38%) | yield (41%) | yield (38%) |
| calculated/found (%) | calculated/found (%) | calculated/found (%) | calculated/found (%) |
| C 37.69/37.75 | C 39.73/39.81 | C 39.86/39.93 | C 32.11/32.17 |
| H 2.87/2.90 | H 2.42/2.47 | H 2.13/2.15 | H 1.71/1.76 |
| N 15.98/16.00 | N 16.85/16.68 | N 16.90/16.75 | N 13.62/13.54 |
| O 4.56/4.45 | - | - | - |
| Zn 18.65/18.75 | Zn 19.66/19.69 | Zn 19.72/19.82 | Zn 15.89/15.67 |
| Cl 20.23/20.15 | Cl 21.32/21.35 | Cl 21.39/21.35 | Cl 17.23/17.33 |
| - | - | - | Br 19.42/19.53 |
Cytotoxic effect of the investigated compounds against glioblastoma (T98G), neuroblastoma (SK-N-AS), lung adenocarcinoma (A549) cell lines and human normal fibroblasts (CCD-1059Sk) determined by MTT assay after 24 h incubation.
| IC50 ± SD (µg/mL) | ||||
|---|---|---|---|---|
| Complex | T98G | SK-N-AS | A549 | CCD-1059-Sk |
|
| 41.25 ± 2.30 | >100 | >100 | >100 |
|
| 32.22 ± 0.92 | 35.59 ± 1.03 | 33.51 ± 1.29 | 18.42 ± 0.37 |
|
| 34.98 ± 1.44 | 81.35 ± 3.31 | 43.08 ± 2.17 | >100 |
|
| 24.29 ± 0.11 | 33.72 ± 0.39 | 34.44 ± 0.75 | 27.27 ± 1.05 |
|
| >100 | >100 | >100 | >100 |
|
| 46.54 ± 1.86 | 41.60 ± 1.93 | 41.34 ± 2.17 | 30.84 ± 1.11 |
|
| >100 | >100 | >100 | >100 |
|
| 30.05 ± 1.81 | 36.17 ± 0.44 | 35.01 ± 0.86 | 33.62 ±0.85 |
|
| >100 | 67.83 ± 2.03 | >100 | >100 |
In vitro antimicrobial activity of ligands and complexes tested.
| Chemicals | L1 | C1 | L2 | C2 | L3 | C3 | L4 | C4 | Ref Drugs |
|---|---|---|---|---|---|---|---|---|---|
| MIC (mg/L) | |||||||||
|
|
| ||||||||
| >1000 | 1000 | 1000 | 500 | >1000 | 1000 | >1000 | >1000 | 0.98 | |
| >1000 | 500 | 1000 | 500 | >1000 | 1000 | 1000 | 500 | 0.98 | |
| 500 | 250 | 250 | 250 | 500 | 500 | >1000 | 500 | 0.12 | |
| >1000 | >1000 | 1000 | 1000 | >1000 | >1000 | 1000 | >1000 | 1.95 | |
| >1000 | 1000 | 500 | 500 | 1000 | >1000 | 1000 | >1000 | 0.24 | |
| >1000 | >1000 | 250 | 500 | 1000 | >1000 | 1000 | >1000 | 0.98 | |
|
|
| ||||||||
| >1000 | >1000 | 1000 | 1000 | >1000 | >1000 | >1000 | >1000 | 0.061 | |
| >1000 | >1000 | 1000 | 1000 | >1000 | >1000 | >1000 | >1000 | 0.015 | |
| >1000 | 1000 | 1000 | 1000 | >1000 | >1000 | >1000 | >1000 | 0.03 | |
| >1000 | >1000 | >1000 | 1000 | >1000 | >1000 | >1000 | >1000 | 0.12 | |
| >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | 0.49 | |
|
|
| ||||||||
| >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | 0.48 | |
| >1000 | >1000 | 1000 | 1000 | >1000 | >1000 | 500 | >1000 | 0.24 | |
| >1000 | >1000 | >1000 | >1000 | 1000 | >1000 | 1000 | >1000 | 0.24 | |
Figure 1FTIR spectrum of free organic ligands L1 and complex C1.
Figure 2FTIR spectrum of free organic ligands L2 and complex C2.
Figure 3FTIR spectrum of free organic ligands L3 and complex C3.
Figure 4FTIR spectrum of free organic ligands L4 and complex C4.
Figure 5Thermal analyses of zinc (II) coordination compounds. TG (green), DTA (blue) and DTG (red) curves for complexes C1–C4.
Temperature ranges and mass losses of thermal decomposition stages of cadmium (II) coordination compounds.
| C1 | C2 | C3 | C4 | m/z | |
|---|---|---|---|---|---|
| Dehydration | 50–120 °C | - | - | - | 17, 18 |
| 1st stage of ligand decomposition | 350–540 °C | 360–520 °C | 310–450 °C | 260–450 °C | 12, 17, 18, 26, 27, 29, 30, 44, 45, 50, 52 |
| 2nd stage of ligand decomposition | 540–725 °C | 520–760 °C | 450–710 °C | 450–740 °C | 12, 13, 17, 18, 22, 26, 27, 29, 30, 35, 36, 37, 38, 41, 44, 45, 46, 70, 72, 79 *, 81 *, 158 *, 160 *, 162 * |
| Residual mass | 12.6% | 11.7% | 17.6% | 6.3% | - |
* signals present only in the mass spectra of C4.
Figure 6(a,b) Molecular structures of C3 and C4 with displacement ellipsoids of nonhydrogen atoms plotted with 50% probability (a). A comparison of the coordination entity structures (b).
Structural data of the coordination polyhedra in C3 and C4.
| i–j | dij (Å) | i–j–k | αijk (°) |
|---|---|---|---|
|
| |||
| Zn1–Cl1 | 2.2667(5) | Cl1–Zn1–Cl2 | 113.01(2) |
| Zn1–Cl2 | 2.2272(5) | Cl1–Zn1–N1 | 103.72(5) |
| Zn1–N1 | 2.0235(15) | Cl1–Zn1–N4(i) | 108.43(5) |
| Zn1–N4(i) | 2.0391(15) | Cl2–Zn1–N1 | 114.30(5) |
| Cl2–Zn1–N4(i) | 102.87(5) | ||
| N1–Zn1–N4(i) | 114.68(6) | ||
|
| |||
| Zn1–Cl1 | 2.2115(9) | Cl1–Zn1–Cl2 | 113.26(3) |
| Zn1–Cl2 | 2.2295(9) | Cl1–Zn1–N1 | 109.05(7) |
| Zn1–N1 | 2.077(3) | Cl1–Zn1–N24 | 115.19(8) |
| Zn1–N24 | 2.030(3) | Cl2–Zn1–N1 | 113.71(8) |
| Cl2–Zn1–N24 | 103.92(8) | ||
| N1–Zn1–N24 | 101.15(10) | ||
| Zn2–Cl3 | 2.2304(9) | Cl3–Zn2–Cl4 | 116.72(3) |
| Zn2–Cl4 | 2.2261(9) | Cl3–Zn2–N21 | 114.10(8) |
| Zn2–N21 | 2.079(3) | Cl3–Zn2–N4 | 107.83(8) |
| Zn2–N4 | 2.048(3) | Cl4–Zn2–N21 | 106.33(7) |
| Cl4–Zn2–N4 | 113.75(8) | ||
| N21–Zn2–N4 | 96.4(1) | ||
Symmetry transformations used to generate equivalent atoms: (i) −x + 1, −y + 1, −z + 1.
Stacking interactions in the structures of C3 and C4. Each ring is indicated by one atom, which belongs solely to this ring. The α is a dihedral angle between planes I and J, β is an angle between Cg(I)–Cg(J) vector and normal to plane I, dp is a perpendicular distance of Cg(I) on ring J plane.
| R(I)•••R(J) | d(Cg•••Cg) (Å) | α (°) | β (°) | dp (Å) |
|
| ||||
| N2•••N1(i) | 4.2575(10) | 1.44(9) | 29.9 | 3.7399(7) |
| N1•••N1(ii) | 3.6918(9) | 0.03(8) | 23.5 | 3.3855(7) |
| N4•••N4(iii) | 3.7548(10) | 0.00(8) | 26.8 | 3.3517(7) |
|
| ||||
| N1•••N2(iv) | 4.0721(18) | 0.72(16) | 25.0 | 3.6686(12) |
| N1•••N1(iv) | 3.8205(16) | 0.03(14) | 15.2 | 3.6865(12) |
| N1•••N24(v) | 3.8155(16) | 10.00(14) | 24.1 | 3.4508(12) |
| N2•••N22(v) | 3.4906(17) | 5.88(17) | 9.3 | 3.3863(13) |
| N4•••N21(v) | 3.6557(16) | 5.72(14) | 21.2 | 3.3775(12) |
Symmetry transformations used to generate equivalent atoms: (i) −x + 2, −y + 1, −z + 1; (ii) −x + 2, −y + 2, −z + 1; (iii) −x + 1, −y + 1, −z; (iv) −x + 1, −y + 1, −z + 1; (v) x, −y + 0.5, z – 0.5; (vi) −x + 2, −y + 1, −z + 2.
Hydrogen bonds in the structures of C3 and C4.
| D–H•••A | d(D–H) (Å) | d(H•••A) (Å) | d(D•••A) (Å) | <(DHA) (°) | Graph-Set |
|
| |||||
| N3–H3•••Cl1(i) | 0.88 | 2.39 | 3.2688(16) | 173 | C (7) |
|
| |||||
| N3–H3•••Cl3(ii) | 0.88 | 2.57 | 3.195(3) | 129 | C (8) |
| N3–H3•••Cl4(iii) | 0.88 | 3.02 | 3.722(3) | 139 | C (8) |
| N23–H23•••Cl2(iv) | 0.88 | 2.71 | 3.459(3) | 143 | C (8) |
| N23–H23•••Cl2(v) | 0.88 | 2.64 | 3.237(3) | 126 | C (8) |
Symmetry transformations used to generate equivalent atoms: (i) x, y, z − 1; (ii) x, −y + 0.5, z – 0.5; (iii) −x + 2, y + 0.5, –z + 1.5; (iv) −x + 1, y + 0.5, −z + 1.5; (v) x, −y + 0.5, z + 0.5.
Figure 7Bioavailability radars for complexes.
Cancer cell line prediction results for the ligand—Pa (probability “to be active”), Pi (probability “to be inactive”).
| Ligand | Pa | Pi | Cell-Line Name | Tissue | Tumor Type |
|---|---|---|---|---|---|
| L3 | 0.587 | 0.029 | Oligodendroglioma | Brain | Glioma |
| L3 | 0.538 | 0.010 | Colon adenocarcinoma | Colon | Adenocarcinoma |
| L3 | 0.490 | 0.022 | Non-small-cell lung carcinoma | Lung | Carcinoma |
| L3 | 0.475 | 0.009 | Pancreatic carcinoma | Pancreas | Carcinoma |
| L3 | 0.439 | 0.043 | Pancreatic carcinoma | Pancreas | Carcinoma |
| L4 | 0.559 | 0.006 | Pancreatic carcinoma | Pancreas | Carcinoma |
| L4 | 0.554 | 0.009 | Colon adenocarcinoma | Colon | Adenocarcinoma |
| L4 | 0.415 | 0.038 | Cervical adenocarcinoma | Cervix | Adenocarcinoma |
| L4 | 0.426 | 0.099 | Oligodendroglioma | Brain | Glioma |
X-ray diffraction data and structure refinement details for C3 and C4.
| Compound | C3 | C4 |
|---|---|---|
| Empirical formula | C22H16Cl4N8Zn2 | C22H14Br2Cl4N8Zn2 |
| Formula weight | 664.97 | 822.77 |
| Temperature (K) | 99.97(4) | 101(2) |
| Crystal system | Triclinic | Monoclinic |
| Space group | ||
| 7.4842(2) | 12.9125(2) | |
| 8.1366(2) | 13.8888(1) | |
| 9.9889(2) | 15.3249(2) | |
| 84.703(2) | 90 | |
| 87.371(2) | 105.483(1) | |
| 80.218(2) | 90 | |
| Volume (Å3) | 596.60(3) | 2648.61(6) |
|
| 1 | 4 |
| Calculated density (g/cm3) | 1.851 | 2.063 |
| Absorption coefficient (mm−1) | 6.858 | 9.743 |
|
| 332 | 1600 |
| Crystal size (mm) | 0.063 × 0.041 × 0.026 | 0.160 × 0.018 × 0.015 |
| Radiation | Cu | Cu |
| 4.447 to 78.664 | 3.552 to 78.928 | |
| Index ranges | −9 ≤ h ≤ 9 | −16 ≤ h ≤ 14 |
| Reflections collected/independent | 11156/2407 | 27186/5268 |
| R | 0.0386 | 0.0393 |
| Completeness (%) | 99.9 | 99.9 |
| Data/restraints/parameters | 2407/0/163 | 5268/0/343 |
| Goodness of fit on | 1.073 | 1.026 |
| Final | ||
| Final | ||
| Largest diff. peak/hole (e•Å−3) | 0.53/−0.34 | 1.07 and −0.91 |